{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:47:39Z","timestamp":1772578059775,"version":"3.50.1"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"US Veterans Affairs research","award":["I01BX005084"],"award-info":[{"award-number":["I01BX005084"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Congenital forms of endocrine hypertension are rare and potentially life-threatening disorders, primarily caused by genetic defects affecting adrenal steroid synthesis and activation pathways. These conditions exhibit diverse clinical manifestations, which can be distinguished by their unique molecular mechanisms and steroid profiles. Timely diagnosis and customized management approach are crucial to mitigate unfavorable outcomes associated with uncontrolled hypertension and other related conditions. Treatment options for these disorders depend on the distinct underlying pathophysiology, which involves specific pharmacological therapies or surgical adrenalectomy in some instances. This review article summarizes the current state of knowledge on the therapeutic management of congenital forms of endocrine hypertension, focusing on familial hyperaldosteronism (FH), congenital adrenal hyperplasia, apparent mineralocorticoid excess, and Liddle syndrome. We provide an overview of the genetic and molecular pathogenesis underlying each disorder, describe the clinical features, and discuss the various therapeutic approaches available and their risk of adverse effects, aiming to improve outcomes in patients with these rare and complex conditions.<\/jats:p>","DOI":"10.1093\/ejendo\/lvad140","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T17:27:01Z","timestamp":1699982821000},"page":"R11-R22","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic management of congenital forms of endocrine hypertension"],"prefix":"10.1093","volume":"189","author":[{"given":"Suranut","family":"Charoensri","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen 40002 , Thailand"},{"name":"Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan , Ann Arbor, MI 48109 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-6181","authenticated-orcid":false,"given":"Richard J","family":"Auchus","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan , Ann Arbor, MI 48109 , United States"},{"name":"Department of Pharmacology, University of Michigan , Ann Arbor, MI 48109 , United States"},{"name":"Endocrinology & Metabolism Section, Medicine Service, LTC Charles S. Kettles VA Medical Center , Ann Arbor, MI 48104 , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"10304","key":"2023120101523872200_lvad140-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2023120101523872200_lvad140-B2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40292-020-00415-9","article-title":"Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension","volume":"27","author":"Rossi","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"3","key":"2023120101523872200_lvad140-B3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"key":"2023120101523872200_lvad140-B4","doi-asserted-by":"crossref","first-page":"e067924","DOI":"10.1136\/bmj-2021-067924","article-title":"Investigating hypertension in younger patients","volume":"376","author":"Rison","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"2023120101523872200_lvad140-B5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/er.2017-00054","article-title":"Screening for endocrine hypertension: an endocrine society scientific statement","volume":"38","author":"Young","year":"2017","journal-title":"Endocr Rev"},{"key":"2023120101523872200_lvad140-B6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/pm-21-48","article-title":"A narrative review of hyporeninemic hypertension-an indicator for monogenic forms of hypertension","volume":"5","author":"Mashmoushi","year":"2022","journal-title":"Pediatr Med"},{"key":"2023120101523872200_lvad140-B7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fped.2019.00263","article-title":"Overview of monogenic or Mendelian forms of hypertension","volume":"7","author":"Raina","year":"2019","journal-title":"Front Pediatr"},{"issue":"4","key":"2023120101523872200_lvad140-B8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.beem.2015.04.010","article-title":"Inherited forms of mineralocorticoid hypertension","volume":"29","author":"Zennaro","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2023120101523872200_lvad140-B9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ecl.2015.02.002","article-title":"Adrenal steroidogenesis and congenital adrenal hyperplasia","volume":"44","author":"Turcu","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2023120101523872200_lvad140-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J Endocrinol"},{"issue":"6","key":"2023120101523872200_lvad140-B11","first-page":"1029","article-title":"The biology of normal zona glomerulosa and aldosterone-producing adenoma: pathological implications","volume":"39","author":"Seccia","year":"2018","journal-title":"Endocr Rev"},{"issue":"2","key":"2023120101523872200_lvad140-B12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1210\/endo-108-2-522","article-title":"Mechanisms of inhibition of aldosterone secretion by adrenocorticotropin","volume":"108","author":"Aguilera","year":"1981","journal-title":"Endocrinology"},{"issue":"1","key":"2023120101523872200_lvad140-B13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanisms of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"Fuller","year":"2012","journal-title":"J Endocrinol"},{"issue":"1","key":"2023120101523872200_lvad140-B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2023120101523872200_lvad140-B15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tem.2012.09.004","article-title":"Aldosterone and cardiovascular disease: the heart of the matter","volume":"24","author":"He","year":"2013","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2023120101523872200_lvad140-B16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"issue":"6","key":"2023120101523872200_lvad140-B17","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2215\/CJN.01410210","article-title":"Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome","volume":"5","author":"Schrier","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2023120101523872200_lvad140-B18","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"(03|3)","key":"2023120101523872200_lvad140-B19","first-page":"157","article-title":"Prevalence of primary aldosteronism in patient's cohorts and in population-based studies\u2014a review of the current literature","volume":"44","author":"Hannemann","year":"2012","journal-title":"Horm Metab Res"},{"issue":"1","key":"2023120101523872200_lvad140-B20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6357","key":"2023120101523872200_lvad140-B21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"issue":"9","key":"2023120101523872200_lvad140-B22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00004872-200018090-00002","article-title":"Primary aldosteronism: learning from the study of familial varieties","volume":"18","author":"Stowasser","year":"2000","journal-title":"J Hypertens"},{"issue":"4","key":"2023120101523872200_lvad140-B23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/sj.jhh.1001821","article-title":"Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting","volume":"19","author":"Pizzolo","year":"2005","journal-title":"J Hum Hypertens"},{"issue":"5","key":"2023120101523872200_lvad140-B24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.111.175083","article-title":"Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms)","volume":"58","author":"Mulatero","year":"2011","journal-title":"Hypertension"},{"issue":"6","key":"2023120101523872200_lvad140-B25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/HYPERTENSIONAHA.110.168740","article-title":"Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation","volume":"57","author":"Aglony","year":"2011","journal-title":"Hypertension"},{"issue":"1","key":"2023120101523872200_lvad140-B26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/01.HYP.31.1.445","article-title":"Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism","volume":"31","author":"Litchfield","year":"1998","journal-title":"Hypertension"},{"issue":"3","key":"2023120101523872200_lvad140-B27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.jhh.1001152","article-title":"Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population?","volume":"15","author":"Gates","year":"2001","journal-title":"J Hum Hypertens"},{"issue":"5","key":"2023120101523872200_lvad140-B28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1067\/mpd.2001.112648","article-title":"Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood","volume":"138","author":"Dluhy","year":"2001","journal-title":"J Pediatr"},{"issue":"1","key":"2023120101523872200_lvad140-B29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0039-128X(94)00010-A","article-title":"Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis","volume":"60","author":"Dluhy","year":"1995","journal-title":"Steroids"},{"key":"2023120101523872200_lvad140-B30","first-page":"1109","article-title":"Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone","volume":"95","author":"Sutherland","year":"1966","journal-title":"Can Med Assoc J"},{"issue":"4","key":"2023120101523872200_lvad140-B31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1210\/edrv-1-4-421","article-title":"Hypertension of childhood with suppressed renin","volume":"1","author":"New","year":"1980","journal-title":"Endocr Rev"},{"issue":"5","key":"2023120101523872200_lvad140-B32","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023120101523872200_lvad140-B33","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1210\/jcem.86.10.7920","article-title":"Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1\/CYP11B2 gene","volume":"86","author":"Fardella","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023120101523872200_lvad140-B34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/01.HYP.28.6.927","article-title":"Inherited forms of mineralocorticoid hypertension","volume":"28","author":"White","year":"1996","journal-title":"Hypertension"},{"issue":"9","key":"2023120101523872200_lvad140-B35","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jcem.85.9.6834","article-title":"Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension","volume":"85","author":"Stowasser","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023120101523872200_lvad140-B36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0960-0760(01)00097-8","article-title":"Familial hyperaldosteronism","volume":"78","author":"Stowasser","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"2023120101523872200_lvad140-B37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2023120101523872200_lvad140-B38","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jch.13597","article-title":"Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism","volume":"21","author":"Izzo","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"2023120101523872200_lvad140-B39","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/jc.2005-0681","article-title":"Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I","volume":"90","author":"Stowasser","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023120101523872200_lvad140-B40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1081\/ERC-120016824","article-title":"Difference of in vivo and in vitro antimineralocorticoid potency of progesterone","volume":"28","author":"Quinkler","year":"2002","journal-title":"Endocr Res"},{"key":"2023120101523872200_lvad140-B41","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1477-7827-11-76","article-title":"Different effects of progesterone and estradiol on chimeric and wild type aldosterone synthase in vitro","volume":"11","author":"Vecchiola","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"2023120101523872200_lvad140-B42","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.ijchy.2020.100029","article-title":"The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism","volume":"5","author":"Rossi","year":"2020","journal-title":"Int J Cardiol Hypertens"},{"issue":"1","key":"2023120101523872200_lvad140-B43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12020-021-02763-5","article-title":"A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy","volume":"74","author":"Sanga","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"2023120101523872200_lvad140-B44","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-14-0444","article-title":"Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy","volume":"172","author":"Riester","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023120101523872200_lvad140-B45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/01443610701667098","article-title":"Conn's syndrome in pregnancy successfully treated with amiloride","volume":"27","author":"Al-Ali","year":"2007","journal-title":"J Obstet Gynaecol"},{"issue":"5","key":"2023120101523872200_lvad140-B46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","article-title":"Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism","volume":"19","author":"Stowasser","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"11","key":"2023120101523872200_lvad140-B47","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/jmg.37.11.831","article-title":"A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22)","volume":"37","author":"Lafferty","year":"2000","journal-title":"J Med Genet"},{"issue":"8","key":"2023120101523872200_lvad140-B48","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.hjh.0000174299.66369.26","article-title":"Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity","volume":"23","author":"So","year":"2005","journal-title":"J Hypertens"},{"issue":"8","key":"2023120101523872200_lvad140-B49","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/HJH.0b013e3283028352","article-title":"Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families","volume":"26","author":"Sukor","year":"2008","journal-title":"J Hypertens"},{"issue":"6","key":"2023120101523872200_lvad140-B50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1365-2265.2006.02674.x","article-title":"No evidence for coding region mutations in the retinoblastoma-associated Kruppel-associated box protein gene (RBaK) causing familial hyperaldosteronism type II","volume":"65","author":"So","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2023120101523872200_lvad140-B51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1440-1681.2008.04882.x","article-title":"Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II","volume":"35","author":"Jeske","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"2023120101523872200_lvad140-B52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 Chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"2023120101523872200_lvad140-B53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11906-019-0934-y","article-title":"Pathogenesis of familial hyperaldosteronism type II: new concepts involving anion channels","volume":"21","author":"Stowasser","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"2023120101523872200_lvad140-B54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41574-020-0382-4","article-title":"Pathogenesis and treatment of primary aldosteronism","volume":"16","author":"Zennaro","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2023120101523872200_lvad140-B55","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/HYPERTENSIONAHA.121.16498","article-title":"Genetics of primary aldosteronism","volume":"79","author":"Scholl","year":"2022","journal-title":"Hypertension"},{"issue":"9","key":"2023120101523872200_lvad140-B56","first-page":"3214","article-title":"Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene","volume":"83","author":"Torpy","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"6018","key":"2023120101523872200_lvad140-B57","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"issue":"8","key":"2023120101523872200_lvad140-B58","doi-asserted-by":"crossref","first-page":"E1567","DOI":"10.1210\/jc.2011-3132","article-title":"Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells","volume":"97","author":"Monticone","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023120101523872200_lvad140-B59","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1210\/en.2012-1241","article-title":"The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line","volume":"153","author":"Oki","year":"2012","journal-title":"Endocrinology"},{"issue":"8","key":"2023120101523872200_lvad140-B60","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","article-title":"A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism","volume":"93","author":"Geller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023120101523872200_lvad140-B61","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/a-1139-2079","article-title":"Immunohistochemistry of the human adrenal CYP11B2 in normal individuals and in patients with primary aldosteronism","volume":"52","author":"Gomez-Sanchez","year":"2020","journal-title":"Horm Metab Res"},{"key":"2023120101523872200_lvad140-B62","doi-asserted-by":"crossref","first-page":"e06315","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"Elife"},{"issue":"8","key":"2023120101523872200_lvad140-B63","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1210\/en.2016-1170","article-title":"CACNA1H(M1549V) mutant calcium channel causes autonomous aldosterone production in HAC15 cells and is inhibited by mibefradil","volume":"157","author":"Reimer","year":"2016","journal-title":"Endocrinology"},{"issue":"9","key":"2023120101523872200_lvad140-B64","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"2023120101523872200_lvad140-B65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19336950.2020.1761171","article-title":"A de novo CACNA1D missense mutation in a patient with congenital hyperinsulinism, primary hyperaldosteronism and hypotonia","volume":"14","author":"Alemany MC","year":"2020","journal-title":"Channels (Austin)"},{"issue":"1","key":"2023120101523872200_lvad140-B66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/HYPERTENSIONAHA.115.06186","article-title":"Genotype-specific steroid profiles associated with aldosterone-producing adenomas","volume":"67","author":"Williams","year":"2016","journal-title":"Hypertension"},{"issue":"15","key":"2023120101523872200_lvad140-B67","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/hmg\/ddx175","article-title":"New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy","volume":"26","author":"Pinggera","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2023120101523872200_lvad140-B68","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/pedi.12512","article-title":"A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia","volume":"18","author":"Flanagan","year":"2017","journal-title":"Pediatr Diabetes"},{"issue":"7397","key":"2023120101523872200_lvad140-B69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nature10989","article-title":"Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations","volume":"485","author":"O\u2019Roak","year":"2012","journal-title":"Nature"},{"key":"2023120101523872200_lvad140-B70","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cphy.c130044","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"issue":"1","key":"2023120101523872200_lvad140-B71","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0889-8529(08)70019-7","article-title":"Steroid 11 beta-hydroxylase deficiency and related disorders","volume":"30","author":"White","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"2023120101523872200_lvad140-B72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MED.0000000000000727","article-title":"The uncommon forms of congenital adrenal hyperplasia","volume":"29","author":"Auchus","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"2023120101523872200_lvad140-B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6065\/apem.2015.20.1.1","article-title":"Clinical and molecular review of atypical congenital adrenal hyperplasia","volume":"20","author":"Sahakitrungruang","year":"2015","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"1","key":"2023120101523872200_lvad140-B74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12020-016-1189-x","article-title":"Clinical perspectives in congenital adrenal hyperplasia due to 11\u03b2-hydroxylase deficiency","volume":"55","author":"Bulsari","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"2023120101523872200_lvad140-B75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41371-017-0002-5","article-title":"Congenital adrenal hyperplasia causing hypertension: an illustrative review","volume":"32","author":"Hinz","year":"2018","journal-title":"J Hum Hypertens"},{"issue":"2","key":"2023120101523872200_lvad140-B76","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12020-018-1691-4","article-title":"Insights on the phenotypic heterogenity of 11\u03b2-hydroxylase deficiency: clinical and genetic studies in two novel families","volume":"62","author":"Valadares","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"2023120101523872200_lvad140-B77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000179494","article-title":"Clinical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency","volume":"16","author":"R\u00f6sler","year":"1982","journal-title":"Horm Res"},{"issue":"4","key":"2023120101523872200_lvad140-B78","first-page":"421","article-title":"Disorders of steroid 11 beta-hydroxylase isozymes","volume":"15","author":"White","year":"1994","journal-title":"Endocr Rev"},{"issue":"10","key":"2023120101523872200_lvad140-B79","doi-asserted-by":"crossref","first-page":"E1620","DOI":"10.1210\/jc.2013-1306","article-title":"A diagnosis not to be missed: nonclassic steroid 11\u03b2-hydroxylase deficiency presenting with premature adrenarche and hirsutism","volume":"98","author":"Reisch","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023120101523872200_lvad140-B80","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13048-018-0450-8","article-title":"Non-classical 11\u03b2-hydroxylase deficiency caused by compound heterozygous mutations: a case study and literature review","volume":"11","author":"Wang","year":"2018","journal-title":"J Ovarian Res"},{"issue":"3","key":"2023120101523872200_lvad140-B81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tem.2008.01.002","article-title":"Steroid 11beta- hydroxylase deficiency congenital adrenal hyperplasia","volume":"19","author":"Nimkarn","year":"2008","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2023120101523872200_lvad140-B82","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-21-0794","article-title":"Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia","volume":"186","author":"Prete","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023120101523872200_lvad140-B83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0039-128X(94)00018-8","article-title":"Long-term treatment of mineralocorticoid excess syndromes","volume":"60","author":"Mantero","year":"1995","journal-title":"Steroids"},{"issue":"8","key":"2023120101523872200_lvad140-B84","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1515\/jpem-2017-0521","article-title":"Three new Brazilian cases of 17\u03b1-hydroxylase deficiency: clinical, molecular, hormonal, and treatment features","volume":"31","author":"Breder","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"2023120101523872200_lvad140-B85","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0888-7543(05)80140-5","article-title":"Localization of the human CYP17 gene (cytochrome P450(17 alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding","volume":"14","author":"Fan","year":"1992","journal-title":"Genomics"},{"issue":"1","key":"2023120101523872200_lvad140-B86","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/edrv-12-1-91","article-title":"17 alpha-hydroxylase\/17,20-lyase deficiency: from clinical investigation to molecular definition","volume":"12","author":"Yanase","year":"1991","journal-title":"Endocr Rev"},{"issue":"49","key":"2023120101523872200_lvad140-B87","doi-asserted-by":"crossref","first-page":"48563","DOI":"10.1074\/jbc.M307586200","article-title":"CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding","volume":"278","author":"Sherbet","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"2023120101523872200_lvad140-B88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ng1097-201","article-title":"The genetic and functional basis of isolated 17,20-lyase deficiency","volume":"17","author":"Geller","year":"1997","journal-title":"Nat Genet"},{"issue":"2","key":"2023120101523872200_lvad140-B89","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jpag.2010.08.018","article-title":"Pubertal delay, hypokalemia, and hypertension caused by a rare form of congenital adrenal hyperplasia","volume":"24","author":"Olson","year":"2011","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"1","key":"2023120101523872200_lvad140-B90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1210\/jc.2003-031021","article-title":"Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency","volume":"89","author":"Costa-Santos","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023120101523872200_lvad140-B91","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0020-7292(81)90007-2","article-title":"17 alpha-hydroxylase deficiency in a genetic male and female sibling pair","volume":"19","author":"Sills","year":"1981","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"2023120101523872200_lvad140-B92","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4158\/EP171987.OR","article-title":"17\u03b1-hydroxylase deficiency is an underdiagnosed disease: high frequency of misdiagnoses in a large cohort of Brazilian patients","volume":"24","author":"Fontenele","year":"2018","journal-title":"Endocr Pract"},{"key":"2023120101523872200_lvad140-B93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jsbmb.2016.02.002","article-title":"Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic","volume":"165","author":"Auchus","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"2023120101523872200_lvad140-B94","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1210\/endo.142.4.8114","article-title":"Minireview: 11beta-hydroxysteroid dehydrogenase type 1\u2014a tissue-specific amplifier of glucocorticoid action","volume":"142","author":"Seckl","year":"2001","journal-title":"Endocrinology"},{"issue":"4812","key":"2023120101523872200_lvad140-B95","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"issue":"1","key":"2023120101523872200_lvad140-B96","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12967-022-03698-9","article-title":"Apparent mineralocorticoid excess: comprehensive overview of molecular genetics","volume":"20","author":"Lu","year":"2022","journal-title":"J Transl Med"},{"issue":"4","key":"2023120101523872200_lvad140-B97","doi-asserted-by":"crossref","first-page":"dgz315","DOI":"10.1210\/clinem\/dgz315","article-title":"Classic and nonclassic apparent mineralocorticoid excess syndrome","volume":"105","author":"Carvajal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023120101523872200_lvad140-B98","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/ng0895-394","article-title":"Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase","volume":"10","author":"Mune","year":"1995","journal-title":"Nat Genet"},{"issue":"5","key":"2023120101523872200_lvad140-B99","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1210\/jcem-44-5-924","article-title":"Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension","volume":"44","author":"New","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023120101523872200_lvad140-B100","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4103\/ijn.IJN_327_16","article-title":"Renal cysts and nephrocalcinosis in 11 beta-hydroxylase deficiency","volume":"27","author":"Abdulla","year":"2017","journal-title":"Indian J Nephrol"},{"issue":"1-2","key":"2023120101523872200_lvad140-B101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s004670000377","article-title":"Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome","volume":"15","author":"Moudgil","year":"2000","journal-title":"Pediatr Nephrol"},{"issue":"17","key":"2023120101523872200_lvad140-B102","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1073\/pnas.95.17.10200","article-title":"A genetic defect resulting in mild low-renin hypertension","volume":"95","author":"Wilson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2023120101523872200_lvad140-B103","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/ajh\/hpy051","article-title":"Serum cortisol and cortisone as potential biomarkers of partial 11\u03b2-hydroxysteroid dehydrogenase type 2 deficiency","volume":"31","author":"Carvajal","year":"2018","journal-title":"Am J Hypertens"},{"issue":"1","key":"2023120101523872200_lvad140-B104","first-page":"135","article-title":"11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess","volume":"18","author":"White","year":"1997","journal-title":"Endocr Rev"},{"key":"2023120101523872200_lvad140-B105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jsbmb.2016.03.010","article-title":"Apparent mineralocorticoid excess","volume":"165","author":"Funder","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2023120101523872200_lvad140-B106","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jsbmb.2016.02.014","article-title":"Apparent mineralocorticoid excess and the long term treatment of genetic hypertension","volume":"165","author":"Razzaghy-Azar","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"2023120101523872200_lvad140-B107","first-page":"2244","article-title":"Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess","volume":"83","author":"Dave-Sharma","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023120101523872200_lvad140-B108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3349\/ymj.2022.0316","article-title":"Diagnosis and treatment of monogenic hypertension in children","volume":"64","author":"Park","year":"2023","journal-title":"Yonsei Med J"},{"issue":"4","key":"2023120101523872200_lvad140-B109","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0039-128X(96)00012-8","article-title":"Apparent mineralocorticoid excess: type I and type II","volume":"61","author":"Mantero","year":"1996","journal-title":"Steroids"},{"issue":"24","key":"2023120101523872200_lvad140-B110","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJM199812103392414","article-title":"Cure of apparent mineralocorticoid excess by kidney transplantation","volume":"339","author":"Palermo","year":"1998","journal-title":"N Engl J Med"},{"issue":"7","key":"2023120101523872200_lvad140-B111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF03343755","article-title":"Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?","volume":"23","author":"Palermo","year":"2000","journal-title":"J Endocrinol Invest"},{"issue":"1-2","key":"2023120101523872200_lvad140-B112","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1515\/jpem-2013-0235","article-title":"Remission of hypertension and electrolyte abnormalities following renal transplantation in a patient with apparent mineralocorticoid excess well documented throughout childhood","volume":"27","author":"Khattab","year":"2014","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2023120101523872200_lvad140-B113","first-page":"395","article-title":"The ENaC channel as the primary determinant of two human diseases: Liddle syndrome and pseudohypoaldosteronism","volume":"17","author":"Schild","year":"1996","journal-title":"Nephrologie"},{"issue":"2","key":"2023120101523872200_lvad140-B114","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.gene.2015.12.061","article-title":"Epithelial sodium channel (ENaC) family: phylogeny, structure-function, tissue distribution, and associated inherited diseases","volume":"579","author":"Hanukoglu","year":"2016","journal-title":"Gene"},{"key":"2023120101523872200_lvad140-B115","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.bbadis.2010.03.010","article-title":"Regulation of the epithelial sodium channel (ENaC) by membrane trafficking","volume":"1802","author":"Butterworth","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2023120101523872200_lvad140-B116","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1113\/jphysiol.2006.109173","article-title":"Open probability of the epithelial sodium channel is regulated by intracellular sodium","volume":"574","author":"Anantharam","year":"2006","journal-title":"J Physiol"},{"issue":"8","key":"2023120101523872200_lvad140-B117","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1073\/pnas.0511184103","article-title":"Liddle's syndrome mutations increase Na+ transport through dual effects on epithelial Na+ channel surface expression and proteolytic cleavage","volume":"103","author":"Knight","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2023120101523872200_lvad140-B118","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1172\/JCI2837","article-title":"Mutations causing Liddle syndrome reduce sodium-dependent downregulation of the epithelial sodium channel in the Xenopus oocyte expression system","volume":"101","author":"Kellenberger","year":"1998","journal-title":"J Clin Invest"},{"issue":"4","key":"2023120101523872200_lvad140-B119","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/HYPERTENSIONAHA.107.097147","article-title":"Epithelial sodium channel: Mendelian versus essential hypertension","volume":"52","author":"Rossier","year":"2008","journal-title":"Hypertension"},{"issue":"3","key":"2023120101523872200_lvad140-B120","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/ijms19030812","article-title":"Liddle syndrome: review of the literature and description of a new case","volume":"19","author":"Tetti","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2023120101523872200_lvad140-B121","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jch.12450","article-title":"Liddle syndrome phenotype in an octogenarian","volume":"17","author":"Pepersack","year":"2015","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"2023120101523872200_lvad140-B122","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00431-011-1581-8","article-title":"Liddle syndrome in a Serbian family and literature review of underlying mutations","volume":"171","author":"Bogdanovi\u0107","year":"2012","journal-title":"Eur J Pediatr"},{"issue":"5","key":"2023120101523872200_lvad140-B123","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jch.12949","article-title":"Liddle syndrome: clinical and genetic profiles","volume":"19","author":"Cui","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"2023120101523872200_lvad140-B124","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248413497257","article-title":"Diuretics: a review and update","volume":"19","author":"Roush","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"2023120101523872200_lvad140-B125","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.02898.x","article-title":"Diagnosis and treatment of low-renin hypertension","volume":"67","author":"Mulatero","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2023120101523872200_lvad140-B126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1085\/jgp.73.3.307","article-title":"On the mechanism of the amiloride-sodium entry site interaction in anuran skin epithelia","volume":"73","author":"Benos","year":"1979","journal-title":"J Gen Physiol"},{"issue":"1","key":"2023120101523872200_lvad140-B127","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1523-1755.1998.00728.x","article-title":"Liddle syndrome: an autosomal dominant form of human hypertension","volume":"53","author":"Warnock","year":"1998","journal-title":"Kidney Int"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/189\/5\/R11\/53827928\/lvad140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/189\/5\/R11\/53827928\/lvad140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T01:53:52Z","timestamp":1701395632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/189\/5\/R11\/7318177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":127,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad140","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,10,17]]}}}